GlassScriptPhysician profile
Mike Ledesma
NPI 1306261599
$7,381.79
in general payments reported to CMS, 2019-2025
46 companies · $782 in 2025
The $782 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,578 · 2022: $1,686 · 2023: $1,713 · 2024: $1,622 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,117.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,423.38 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $948.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $871.96 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $401.68 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $362.38 | 2022-2024 | |
| Esperion Therapeutics, INC. | $323.31 | 2021-2024 | Nexletol |
| Amarin Pharma, INC. | $298.47 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $204.60 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.05 | 2022-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $199.52 | 2022 | |
| Sumitomo Pharma America, INC. | $162.52 | 2023-2024 | Gemtesa |
| Pfizer INC. | $153.82 | 2021-2025 | |
| Corcept Therapeutics | $149.83 | 2022-2024 | Korlym |
| Merck Sharp & Dohme LLC | $141.38 | 2021-2025 | Belsomra, Capvaxive, Gardasil 9 |
| Abbott Laboratories | $122.52 | 2021-2025 | Freestyle Libre 3 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $109.30 | 2023-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $100.11 | 2021-2025 | Elaprase, Trintellix |
| Next Science LLC | $97.78 | 2023 | Xperience, Blastx, Surgx |
| Insulet Corporation | $89.28 | 2023 | Omnipod |
| Glaxosmithkline, LLC. | $86.40 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sunovion Pharmaceuticals INC. | $85.23 | 2022 | |
| Atland Pharmaceuticals, LLC | $82.19 | 2024 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.57 | 2022-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $70.03 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $67.30 | 2021-2022 | |
| Shield Therapeutics INC | $65.56 | 2023-2025 | Accrufer |
| Amgen INC. | $42.05 | 2025 | Tavneos, Evenity, Prolia |
| Phathom Pharmaceuticals, INC. | $36.13 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $34.80 | 2025 | |
| Antares Pharma, INC. | $33.26 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Kowa Pharmaceuticals America, INC. | $32.52 | 2022 | |
| Gilead Sciences, INC. | $31.56 | 2021 | |
| Horizon Therapeutics Plc | $26.53 | 2021-2022 | |
| Mylan Specialty L.P. | $24.19 | 2023 | Yupelri |
| Xeris Pharmaceuticals, INC. | $24.09 | 2024 | Recorlev |
| Mannkind Corporation | $23.10 | 2022 | |
| Evoke Pharma, INC. | $22.55 | 2022 | |
| Althera Pharmaceuticals LLC | $20.62 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $20.00 | 2023 | Opsumit |
| Biohaven Pharmaceuticals, INC. | $18.94 | 2021 | |
| Recordati_rare_diseases_inc. | $18.40 | 2023 | Signifor Lar, Isturisa |
| Ardelyx, INC. | $18.40 | 2024 | Ibsrela |
| Tolmar, INC. | $18.04 | 2023 | |
| Currax Pharmaceuticals LLC | $15.32 | 2025 | Contrave |
| Optinose US, INC. | $14.54 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mike Ledesma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.